<p>，/PRNewswire/ -- 上海 StairMed 科技有限公司（&#34;StairMed&#34;或&#34;公司&#34;）最近宣布完成一轮总额为 5 亿元人民币的战略融资。该轮融资由阿里巴巴主导，现有股东包括腾讯、Fountainbridge Capital、OrbiMed、Oriza Seed、启明创投、Lilly Asia Ventures (LAV) 和 Source Code Capital 等也积极参与。Springhill Fund 担任独家财务顾问。这轮融资使 StairMed 在过去一年内的总融资额超过了 11 亿元人民币。这一轮融资也标志着阿里巴巴和腾讯在脑机接口领域的罕见联合投资。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p><strong>加速临床里程碑：脑机接口系统的多中心试验定于 2026 年中期进行，神经调节管线推进</strong></p>
<p>随着这轮融资的完成，StairMed 计划加速其技术平台和临床项目的发展，基于去年完成的三例成功的脑机接口（BMI）系统临床植入。在 2026 年初，StairMed 利用其自主研发的手术机器人完成了 256 通道无线高通量侵入式 BMI 系统（WRS02）的植入，作为注册过程的一部分，并成功验证了脑控交互功能。这个里程碑代表了 StairMed 的重大技术进步，并标志着中国首个 256 通道侵入式 BMI 的临床试验。该系统目前是中国唯一获得国家药品监督管理局（NMPA）创新医疗器械绿色通道的侵入式 BMI。</p>
<p>展望未来，StairMed 计划启动其临床开发项目的下一阶段。大规模的多中心注册临床试验预计将在 2026 年中期开始，目标是在一年内招募并植入约 40 名患者。到 2026 年底，StairMed 的累计植入患者数量预计将达到数十人，代表着侵入式 BMI 技术临床发展的重要一步。</p>
<p>与其脑控产品开发并行，StairMed 正在扩展其神经调节产品组合。</p>
<p>凭借其超灵活的微电极技术，StairMed 开发了一种闭环、超低损伤的深脑刺激（DBS）系统，其性能在微观尺寸和灵活性等核心指标上与国际领先系统相当。该系统已在四名患者中植入，作为临床研究的一部分，验证了其治疗潜力。公司计划在 2027 年启动该系统的正式临床试验，目标是为帕金森病、癫痫和其他神经系统疾病的患者提供变革性的治疗选择，进一步巩固 StairMed 在全球 BMI 领域的地位。</p>
<p><strong>与技术领袖的战略对接推动下一代人机交互</strong></p>
<p>BMI 行业的快速发展越来越受到计算和人工智能（AI）进步的推动。</p>
<p>StairMed 创始人李雪表示：&#34;我们感谢现有股东自公司早期以来的持续支持，特别是作为核心产业投资者的腾讯。我们也欢迎阿里巴巴和 SDIC Unity Capital 参与这一轮融资。&#34;李指出，领先互联网和科技公司深度参与的战略重要性，&#34;BMI 不仅是一项新兴的医疗技术，也是生命科学与信息技术的交汇点。这些行业领袖在多模态大模型、计算基础设施、智能硬件和生态系统开发方面的深厚专业知识与 StairMed 在 BMI 硬件和临床转化方面的优势紧密契合。这种合作将使我们能够共同开发下一代智能 BMI 系统和前沿应用生态系统。这不仅是对医疗创新的投资，更是对人机交互长期潜力的战略押注。&#34;</p>
<p><strong>关于 StairMed</strong></p>
<p>上海 StairMed 科技有限公司成立于 2021 年，是微创植入式脑机接口（BMI）领域的先驱。</p>
<p>StairMed 开发了电极、系统、算法和手术机器人等专有技术。公司创造了宽度仅为人类头发百分之一的超灵活电极和世界上最小的无线 BMI 植入物。2025 年，公司完成了中国首个侵入式 BMI 的前瞻性临床试验，其产品已获得国家药品监督管理局创新医疗器械绿色通道的准入。</p>
<p>StairMed 专注于脑控和神经调节两个主要领域，为运动障碍和神经疾病患者提供创新疗法。其长期使命是实现脑与机器智能的融合。</p>
<p>来源：StairMed</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy"/></p>

腾讯控股(ADS)

腾讯控股(ADR)

2 倍做多阿里巴巴 ETF - KraneShares

2 倍做多 BABA ETF - GraniteShares

<p>上海斯泰尔医疗科技有限公司在阿里巴巴的主导下，成功获得 5 亿人民币的战略融资，腾讯及其他投资者也参与了此次融资。这笔资金将加速其脑机接口（BMI）技术的发展，此前已成功进行临床植入。斯泰尔计划在 2026 年中期启动大规模临床试验，并扩展其神经调节产品组合。该公司旨在通过与科技领袖的合作，增强人机交互，力争成为 BMI 领域的关键参与者</p>

<p>, /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. (&#34;StairMed&#34; or &#34;the Company&#34;) recently announced the closing of a strategic financing round totaling RMB 500 million. The round was led by Alibaba, with strong continued participation from existing shareholders including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Ventures (LAV), and Source Code Capital, etc. Springhill Fund served as the exclusive financial advisor. This latest round brings StairMed's total funding raised in the past year to over RMB 1.1 billion. This round also marks a rare joint investment by Alibaba and Tencent in the brain-machine interface sector.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- 上海 StairMed 科技有限公司（&#34;StairMed&#34;或&#34;公司&#34;）最近宣布完成一轮总额为 5 亿元人民币的战略融资。该轮融资由阿里巴巴主导，现有股东包括腾讯、Fountainbridge Capital、OrbiMed、Oriza Seed、启明创投、Lilly Asia Ventures (LAV) 和 Source Code Capital 等也积极参与。Springhill Fund 担任独家财务顾问。这轮融资使 StairMed 在过去一年内的总融资额超过了 11 亿元人民币。这一轮融资也标志着阿里巴巴和腾讯在脑机接口领域的罕见联合投资。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p><strong>Accelerating Clinical Milestones: Multi-Center Trials for BMI Systems Set for Mid-2026, Neuromodulation Pipeline Advances</strong></p>
<div class="lb-trans"><p><strong>加速临床里程碑：脑机接口系统的多中心试验定于 2026 年中期进行，神经调节管线推进</strong></p>
</div><p>With the closing of this financing round, StairMed plans to accelerate development of its technology platform and clinical programs, building on three successful clinical implants of its brain-machine interface (BMI) system completed last year. In early 2026, StairMed used its proprietary surgical robot to complete implantation of its 256-channel wireless high-throughput invasive BMI system (WRS02) as part of the registration process and successfully validated brain-controlled interaction functions. This milestone represents a significant technological advancement for StairMed and marks the first clinical trial of a 256-channel invasive BMI in China. The system is currently the only invasive BMI in China to receive access to the National Medical Products Administration (NMPA) Green Channel for Innovative Medical Devices.</p>
<div class="lb-trans"><p>随着这轮融资的完成，StairMed 计划加速其技术平台和临床项目的发展，基于去年完成的三例成功的脑机接口（BMI）系统临床植入。在 2026 年初，StairMed 利用其自主研发的手术机器人完成了 256 通道无线高通量侵入式 BMI 系统（WRS02）的植入，作为注册过程的一部分，并成功验证了脑控交互功能。这个里程碑代表了 StairMed 的重大技术进步，并标志着中国首个 256 通道侵入式 BMI 的临床试验。该系统目前是中国唯一获得国家药品监督管理局（NMPA）创新医疗器械绿色通道的侵入式 BMI。</p>
</div><p>Looking ahead, StairMed plans to initiate the next phase of its clinical development program. Large-scale, multi-center registration clinical trials are on track to begin in mid-2026, with the goal of enrolling and implanting approximately 40 patients within the year. By the end of 2026, StairMed's cumulative number of patients implanted is expected to reach several dozen, representing a significant step in the clinical development of invasive BMI technology.</p>
<div class="lb-trans"><p>展望未来，StairMed 计划启动其临床开发项目的下一阶段。大规模的多中心注册临床试验预计将在 2026 年中期开始，目标是在一年内招募并植入约 40 名患者。到 2026 年底，StairMed 的累计植入患者数量预计将达到数十人，代表着侵入式 BMI 技术临床发展的重要一步。</p>
</div><p>In parallel with its brain-controlled product development, StairMed is expanding its neuromodulation portfolio.</p>
<div class="lb-trans"><p>与其脑控产品开发并行，StairMed 正在扩展其神经调节产品组合。</p>
</div><p>Drawing on its ultra-flexible microelectrode technology, StairMed has developed a closed-loop, ultra-low-damage deep brain stimulation (DBS) system, with performance comparable to leading international systems on core metrics such as microscale dimensions and flexibility. It has already been implanted in four patients as part of clinical research, validating its therapeutic potential. The Company plans to initiate formal clinical trials for this system in 2027, targeting transformative treatment options for patients with Parkinson's disease, epilepsy, and other neurological disorders, and further strengthening StairMed's position in the global BMI landscape.</p>
<div class="lb-trans"><p>凭借其超灵活的微电极技术，StairMed 开发了一种闭环、超低损伤的深脑刺激（DBS）系统，其性能在微观尺寸和灵活性等核心指标上与国际领先系统相当。该系统已在四名患者中植入，作为临床研究的一部分，验证了其治疗潜力。公司计划在 2027 年启动该系统的正式临床试验，目标是为帕金森病、癫痫和其他神经系统疾病的患者提供变革性的治疗选择，进一步巩固 StairMed 在全球 BMI 领域的地位。</p>
</div><p><strong>Strategic Alignment with Technology Leaders Drives Next-Generation Human-Machine Interaction</strong></p>
<div class="lb-trans"><p><strong>与技术领袖的战略对接推动下一代人机交互</strong></p>
</div><p>The rapid evolution of the BMI industry is increasingly driven by advances in computing and artificial intelligence (AI).</p>
<div class="lb-trans"><p>BMI 行业的快速发展越来越受到计算和人工智能（AI）进步的推动。</p>
</div><p>Li Xue, founder of StairMed, commented, &#34;We are grateful to our existing shareholders for their continued support since our early days, particularly Tencent as a core industrial investor. We also welcome Alibaba and SDIC Unity Capital to this round.&#34; Li noted the strategic importance of deep involvement from leading internet and technology companies, &#34;BMI is not only an emerging medical technology, but also a point of convergence between life sciences and information technology. The deep expertise of these industry leaders in multi-modal large models, computing infrastructure, intelligent hardware, and ecosystem development aligns closely with StairMed's strengths in BMI hardware and clinical translation. This partnership will enable us to co-develop next-generation intelligent BMI systems and cutting-edge application ecosystems. This is more than an investment in medical innovation—it is a strategic bet on the long-term potential of human-machine interaction.&#34;</p>
<div class="lb-trans"><p>StairMed 创始人李雪表示：&#34;我们感谢现有股东自公司早期以来的持续支持，特别是作为核心产业投资者的腾讯。我们也欢迎阿里巴巴和 SDIC Unity Capital 参与这一轮融资。&#34;李指出，领先互联网和科技公司深度参与的战略重要性，&#34;BMI 不仅是一项新兴的医疗技术，也是生命科学与信息技术的交汇点。这些行业领袖在多模态大模型、计算基础设施、智能硬件和生态系统开发方面的深厚专业知识与 StairMed 在 BMI 硬件和临床转化方面的优势紧密契合。这种合作将使我们能够共同开发下一代智能 BMI 系统和前沿应用生态系统。这不仅是对医疗创新的投资，更是对人机交互长期潜力的战略押注。&#34;</p>
</div><p><strong>About StairMed</strong></p>
<div class="lb-trans"><p><strong>关于 StairMed</strong></p>
</div><p>Shanghai StairMed Technology Co., Ltd., founded in 2021, is a pioneer in the field of minimally invasive implantable brain-machine interfaces (BMI).</p>
<div class="lb-trans"><p>上海 StairMed 科技有限公司成立于 2021 年，是微创植入式脑机接口（BMI）领域的先驱。</p>
</div><p>StairMed has developed proprietary technologies for electrodes, systems, algorithms, and surgical robotics. The Company has created ultra-flexible electrodes as fine as one-hundredth the width of a human hair and the world's smallest wireless BMI implant. In 2025, it completed China's first prospective clinical trial for an invasive BMI, and its product has been granted access to the NMPA Green Channel for Innovative Medical Devices.</p>
<div class="lb-trans"><p>StairMed 开发了电极、系统、算法和手术机器人等专有技术。公司创造了宽度仅为人类头发百分之一的超灵活电极和世界上最小的无线 BMI 植入物。2025 年，公司完成了中国首个侵入式 BMI 的前瞻性临床试验，其产品已获得国家药品监督管理局创新医疗器械绿色通道的准入。</p>
</div><p>StairMed focuses on two primary areas—brain control and neuromodulation—to deliver innovative therapies for patients with movement disorders and neurological diseases. Its long-term mission is to achieve the integration of brain and machine intelligence.</p>
<div class="lb-trans"><p>StairMed 专注于脑控和神经调节两个主要领域，为运动障碍和神经疾病患者提供创新疗法。其长期使命是实现脑与机器智能的融合。</p>
</div><p>SOURCE StairMed</p>
<div class="lb-trans"><p>来源：StairMed</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9Q04yNTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIwMjQxUFJfTkVXU19VU1BSX19fX19DTjI1ODAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN25802&amp;Transmission_Id=202604020241PR_NEWS_USPR_____CN25802&amp;DateId=20260402"/></p>

02:41 ETStairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent

- 上海 StairMed 技术有限公司完成 5 亿人民币的战略融资，主要投资方为阿里巴巴和腾讯等。  
- 融资后，StairMed 计划加速其脑机接口技术平台的开发，并将在 2026 年中开始多中心临床试验。  
- 公司预计到 2026 年底，植入患者人数将达数十名，推动侵入性脑机接口技术的临床进展。

02:41 ETStairMed 获得阿里巴巴领投、腾讯参投的 5 亿元人民币融资